High Heregulin mRNA, HER3 Linked to Poor Survival in Oropharyngeal Carcinoma
the Cancer Therapy Advisor take:
Independent associations between high heregulin messenger RNA (mRNA) and high human epidermal growth factor receptor 3 (HER3) protein levels and poor overall survival (OS) were discovered in patients with oropharyngeal squamous cell carcinoma (OPSCC), according to an article published online in the journal Cancer.
The investigators examined 96 primary tumor specimens from patients with OPSCC and analyzed for heregulin mRNA, HER3, and human epidermal growth factor receptor 2 (HER2), using in situ hybridization and immunohistochemistry, respectively.
Results showed heregulin mRNA levels greater than the median value were significantly associated with poor OS (HR, 8.48; 95% CI: 2.17, 33.17; P=0.002) but not disease-free survival (HR, 1.52; 95% CI: 0.64, 3.65; P=0.341) in patients with OPSCC.
Furthermore, a negative correlation was determined between heregulin mRNA and OS in patients with p16-positive (P=0.049) and p16-negative (P=0.091) OPSCC.
Similarly, HER3 levels greater than the median were also associated with poor OS (HR, 4.68; 95% CI: 1.47, 14.90; P=0.009) in patients with OPSCC.
An independent correlation was identified for epidermal growth factor receptor (HER) levels and disease-free survival (P=0.025), while HER was also inversely related to p16 status (P=0.012).
Using The Cancer Genome Atlas database, it was determined that head and neck squamous cell carcinoma exhibited higher levels of heregulin compared to other solid tumor types.
Associations between heregulin mRNA and HER3 protein levels and overall survival discovered in oropharyngeal squamous cell carcinoma.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC